A four-group gene expression signature from urine to classify prostate cancer aggression
Prostate cancer will affect half of all men over 60 yet only a very small proportion of these men will die of the disease. Therefore, there is a need to determine which men with prostate cancer need treatment and which men do not require treatment. Current assessment of cancer aggressiveness divides tumours into three groups of low, intermediate and high risk. However, there are several problems with current methods of patient assessment. Biopsies can miss aggressive cancer, and Magnetic Resonance Imaging (MRI) is improving although not totally reliable. Many patients are repeatedly biopsied on an active surveillance regime as it is not possible to predict in advance which cancers will progress and require treatment. There is an urgent need to develop new assays that are better at detecting aggressive disease that can improve stratification of patients for active surveillance.
In this webinar, Dr. Jeremy Clark, from the University of East Anglia, will discuss the use of a NanoString® nCounter® Custom CodeSet to develop a gene expression signature from urine that identifies and classifies prostate cancer into one of four risk classifiers for cancer aggression.
For Research Use Only. Not for Use in Diagnostic Procedures.